Dafna Capital Management LLC and Fariba Fischel Ghodsian Buys $0 in Derivatives of Stereotaxis Inc (STXS) — SEC Form 4, Nov 12, 2026

SEC Form 4 · No Market Transaction
Purchase

Non-market transaction reported.

Reporting Owners
TXN 2026-11-09 · FILED 2026-11-12
Filing Lag 2 business days within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Filing Date
2026-11-12
Report Date
2026-11-12
Accession No.
0001104659-26-126196
Accepted At
2026-11-12 21:01 UTC
Reporting Owners
Name Relationship
Dafna Capital Management LLC CIK 0001389933
10% Owner
Fariba Fischel Ghodsian CIK 0001733969
10% Owner
Derivative Securities Transactions
Title Strike Date Type Shares Price Expiration Underlying Ownership
Convertible Promissory NotesF2F1F3F4 2026-11-09 P - Purchase A $2,000,000.00 2029-11-09 1,652,892 Common Stock Indirect See footnote
Footnotes (4)
F1
On November 9, 2026, the Issuer entered into a note purchase agreement (the "Purchase Agreement") with certain investors, including DAFNA Capital Management, LLC ("DAFNA"), on behalf of DAFNA LifeScience, L.P. and DAFNA LifeScience Select, L.P. (the "Funds"), for the purchase of convertible promissory notes (the "Notes"). DAFNA acquired Notes under the Purchase Agreement in the aggregate principal amount, and for a total purchase price, of $2,000,000. The Notes have a maturity date of November 9, 2029 and bear interest at a rate of 10% per annum, which may be paid in cash or in kind be adding the amount of interest to the principal balance. Show more
F2
The conversion of the Notes will be made based on a conversion rate of $1.21 per share. Show more
F3
The Notes and accrued interest are convertible into shares of the Issuer's Common Stock at the election of the holders at any time prior to the maturity date or the consummation of a merger, sale, consolidation or reorganization of the Issuer, subject to a 19.9% beneficial ownership blocker. If the Notes cannot be fully converted due to the NYSE American exchange cap, then no portion of the Notes will convert into the Issuer's Common Stock until the Issuer has obtained stockholder approval to the waiver of the exchange cap. Show more
F4
The reported securities are directly owned by the Funds. DAFNA may be deemed to beneficially own the reported securities as the investment manager and general partner of the Funds. The reported securities may also be deemed beneficially owned by Dr. Fariba Ghodsian as the Chief Investment Officer of DAFNA. DAFNA and Dr. Ghodsian disclaim beneficial ownership of the reported securities except to the extent of its and her respective pecuniary interest therein, if any. This report shall not be deemed an admission that DAFNA or Dr. Ghodsian is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Show more
5%+ Holders · 13D/G 2 filers
Other insiders at Stereotaxis Inc
All Stereotaxis Inc insider activity
GET /v1/forms/4/0001104659-26-126196 API docs
View Original SEC Filing